Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.50 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.46 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953159 | 1.00 | ERN1 (0.53) | ERN1ALDH1A1TDP1TRIM24TRIM33 | |
| SCHEMBL286553 | 0.92 | ALDH1A1 (0.53) | ERN1ALDH1A1TDP1TRIM24TRIM33 | |
| SCHEMBL5361924 | 0.84 | ALDH1A1 (0.69) | ERN1ALDH1A1TDP1TRIM24TRIM33 | |
| SCHEMBL6234401 | 0.84 | ERN1 (0.53) | ERN1ALDH1A1TDP1TRIM24TRIM33 | |
| SCHEMBL1494078 | 0.84 | ALDH1A1 (0.68) | ERN1ALDH1A1TDP1HPGDKDM4E | |
| SCHEMBL29818672 | 0.82 | ALDH1A1 (0.65) | ERN1ALDH1A1TDP1HPGDKDM4E | |
| SCHEMBL282147 | 0.82 | ALDH1A1 (0.54) | ERN1ALDH1A1TDP1HPGDKDM4E | |
| SCHEMBL1004432 | 0.80 | ALDH1A1 (0.57) | ERN1ALDH1A1TDP1TRIM24TRIM33 | |
| SCHEMBL29459687 | 0.80 | ALDH1A1 (0.57) | ERN1ALDH1A1TDP1TRIM24TRIM33 | |
| SCHEMBL1002368 | 0.80 | ALDH1A1 (0.69) | ERN1ALDH1A1TDP1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210289794-A1 | COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-23 | — | — | US | disclosed |
| CN-106117392-A | A kind of chitosan graft vanilloyl derivant and its preparation method and application | 河南科技学院 | 2016-11-16 | — | — | CN | disclosed |
| CN-100478022-C | Synergistic composition for treating hyperlipidemia | COUNCIL SCIENT IND RES (IN) | 2009-04-15 | — | — | CN | disclosed |
| US-20070027138-A1 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT | 2007-02-01 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| US-7166588-B2 | Derivatives and analogs of galanthamine | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2007-01-23 | — | — | US | disclosed |
| CN-1893965-A | Synergistic composition for treating hyperlipemia | COUNCIL SCIENT IND RES (IN) | 2007-01-10 | — | — | CN | disclosed |
| US-6989165-B2 | Synergistic composition for treating hyperilipdemia | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-01-24 | — | — | US | disclosed |
| WO-2005070442-A1 | A SYNERGISTIC COMPOSITION FOR TREATING HYPERLIPIDEMIA | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2005-08-04 | — | — | WO | disclosed |
| US-20050136138-A1 | Synergistic composition for treating hyperilipdemia | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2005-06-23 | — | — | US | disclosed |
| EP-1181294-B1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | SANOCHEMIA PHARMAZEUTIKA AG (AT) | 2004-03-31 | — | — | EP | disclosed |
| EP-1181294-A1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | Sanochemia Pharmazeutika Aktiengesellschaft (AT) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001074820-A1 | NOVEL DERIVATIVES AND ANALOGUES OF GALANTHAMIN | SANOCHEMIA PHARMAZEUTIKA AKTIENGESELLSCHAFT (AT) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027138-A1 | Derivatives and analogs of galanthamine | GALR2, GALR1, GALR3 | ERN1 4264/4885ALDH1A1 2196/4885TDP1 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.